BR9611015A - Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto - Google Patents
Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um compostoInfo
- Publication number
- BR9611015A BR9611015A BR9611015-5A BR9611015A BR9611015A BR 9611015 A BR9611015 A BR 9611015A BR 9611015 A BR9611015 A BR 9611015A BR 9611015 A BR9611015 A BR 9611015A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- acceptable salt
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 231100000252 nontoxic Toxicity 0.000 title abstract 2
- 230000003000 nontoxic effect Effects 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 title 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 abstract 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/58—One oxygen atom, e.g. butenolide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/60—Two oxygen atoms, e.g. succinic anhydride
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/62—Three oxygen atoms, e.g. ascorbic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/64—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/66—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/83—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/94—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Furan Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Seasonings (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
"COMPOSTO, COMPOSIçãO FARMACêUTICA E PROCESSO PARA O TRATAMENTO DE UMA DOENçA INFLAMATóRIA SUSCETìVEL AO TRATAMENTO COM UM AGENTE NãO-TóXICO ANTI-INFLAMATóRIO NãO-ESTERóIDE, SAL FARMACEUTICAMENTE ACEITáVEL, UTILIZAçãO DE UM COMPOSTO". A invenção abrange o composto inédito de fórmula (I) que é útil no tratamento de doenças mediadas por ciclooxigenase-2. A invenção também abrange determinadas composições para o tratamento de doenças mediadas pro ciclooxigenase-2 compreendendo compostos de fórmula (I).
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US537195P | 1995-10-13 | 1995-10-13 | |
GBGB9602939.2A GB9602939D0 (en) | 1996-02-13 | 1996-02-13 | (Methylsulfony)phenyl-2-(5h)-furanones as cox-2 inhibitors |
US1163796P | 1996-02-14 | 1996-02-14 | |
GBGB9605645.2A GB9605645D0 (en) | 1996-03-18 | 1996-03-18 | (Methylsulfonyl)phenyl-2-(5H)- furanones as cox-2 inhibitors |
PCT/CA1996/000682 WO1997014691A1 (en) | 1995-10-13 | 1996-10-09 | (methylsulfonyl)phenyl-2-(5h)-furanones as cox-2 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9611015A true BR9611015A (pt) | 1999-09-14 |
Family
ID=27451401
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9611015-5A BR9611015A (pt) | 1995-10-13 | 1996-10-09 | Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto |
Country Status (39)
Country | Link |
---|---|
EP (1) | EP0863891B1 (pt) |
JP (2) | JP3337476B2 (pt) |
KR (1) | KR100354940B1 (pt) |
CN (1) | CN1203066C (pt) |
AT (1) | ATE229515T1 (pt) |
AU (1) | AU703871B2 (pt) |
BG (1) | BG63391B1 (pt) |
BR (1) | BR9611015A (pt) |
CA (1) | CA2233178C (pt) |
CO (1) | CO4770965A1 (pt) |
CZ (1) | CZ295764B6 (pt) |
DE (2) | DE69625374T2 (pt) |
DK (1) | DK0863891T3 (pt) |
DZ (1) | DZ2103A1 (pt) |
EA (1) | EA000795B1 (pt) |
EE (1) | EE03969B1 (pt) |
ES (1) | ES2187675T3 (pt) |
HK (1) | HK1016980A1 (pt) |
HR (1) | HRP960458B1 (pt) |
HU (1) | HU222785B1 (pt) |
IL (1) | IL123699A (pt) |
IS (1) | IS2148B (pt) |
LU (1) | LU91145I2 (pt) |
MX (1) | MX9802836A (pt) |
MY (1) | MY141773A (pt) |
NL (1) | NL300175I2 (pt) |
NO (1) | NO321042B1 (pt) |
NZ (1) | NZ319090A (pt) |
PE (1) | PE17198A1 (pt) |
PL (1) | PL188918B1 (pt) |
PT (1) | PT863891E (pt) |
RO (1) | RO119884B1 (pt) |
RS (1) | RS49885B (pt) |
SA (1) | SA96170405B1 (pt) |
SK (1) | SK282639B6 (pt) |
TR (1) | TR199800585T2 (pt) |
TW (1) | TW426679B (pt) |
UA (1) | UA57002C2 (pt) |
WO (1) | WO1997014691A1 (pt) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515014B2 (en) | 1995-06-02 | 2003-02-04 | G. D. Searle & Co. | Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
HUP9901155A3 (en) | 1996-02-13 | 2003-04-28 | Astrazeneca Ab | Quinazoline derivatives as vegf inhibitors |
DE69709319T2 (de) | 1996-03-05 | 2002-08-14 | Astrazeneca Ab, Soedertaelje | 4-anilinochinazolin derivate |
US5883267A (en) * | 1996-05-31 | 1999-03-16 | Merck & Co., Inc. | Process for making phenyl heterocycles useful as cox-2 inhibitors |
ES2201466T3 (es) * | 1997-03-14 | 2004-03-16 | MERCK FROSST CANADA & CO. | `(metilsulfonil)fenil-2-(5h)-furanonas con enlace con oxigeno como inhibidores de cox-2`. |
US6071954A (en) * | 1997-03-14 | 2000-06-06 | Merk Frosst Canada, Inc. | (methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors |
US6307047B1 (en) | 1997-08-22 | 2001-10-23 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
US6525053B1 (en) | 1997-08-22 | 2003-02-25 | Abbott Laboratories | Prostaglandin endoperoxide H synthase biosynthesis inhibitors |
AU2247599A (en) * | 1997-09-24 | 1999-04-12 | Merck & Co., Inc. | Process of making 3-aryloxy, 4-aryl furan-2-ones useful as inhibitors of cox-2 |
FR2770131A1 (fr) * | 1997-10-27 | 1999-04-30 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
GB2330833A (en) * | 1997-10-29 | 1999-05-05 | Merck & Co Inc | PREPARATION OF 4-(4-Methylsulfonylphenyl)-2-furanones USEFUL AS COX-2 INHIBITORS |
EP1028951A1 (en) * | 1997-10-30 | 2000-08-23 | Merck Frosst Canada Inc. | Diaryl-5-alkyl-5-methyl-2(5h)-furanones as selective cyclooxygenase-2 inhibitors |
US6133292A (en) * | 1997-10-30 | 2000-10-17 | Merck Frosst Canada & Co. | Diaryl-5-alkyl-5-methyl-2-(5H)-furanones as selective cyclooxygenase-2-inhibitors |
FR2771005B1 (fr) * | 1997-11-18 | 2002-06-07 | Union Pharma Scient Appl | Nouvelle association pharmaceutique a activite analgesique |
US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
CA2322824A1 (en) * | 1998-03-13 | 1999-09-16 | Merck & Co., Inc. | Combination therapy and composition for acute coronary ischemic syndrome and related conditions |
ES2140354B1 (es) * | 1998-08-03 | 2000-11-01 | S A L V A T Lab Sa | Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2. |
JP2002528435A (ja) * | 1998-10-27 | 2002-09-03 | メルク エンド カムパニー インコーポレーテッド | メチルチオフェニルヒドロキシケトンの合成 |
ES2213007T3 (es) * | 1999-04-14 | 2004-08-16 | Pacific Corporation | Derivados de 4,5-diaril-3(2h)-furanona como inhibidores de la ciclooxigenasa-2. |
EP1090915B1 (en) * | 1999-10-08 | 2009-05-27 | Merial | Polymorphic B form of 3-(cyclopropylmethoxy)-4-¬-4-(methylsulfonyl)phenyl - 5,5-dimethyl-5H-furan-2-one |
FR2799462B1 (fr) * | 1999-10-08 | 2004-05-28 | Merial Sas | Procede de preparation d'inhibiteurs cox-2 |
SK287401B6 (sk) | 1999-11-05 | 2010-09-07 | Astrazeneca Ab | Deriváty chinazolínu, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie |
EP1104759B1 (en) | 1999-12-03 | 2003-10-22 | Pfizer Products Inc. | Heteroaryl phenyl pyrazole compounds as anti-inflammatory/analgesic agents |
PT1104758E (pt) | 1999-12-03 | 2003-12-31 | Pfizer Prod Inc | Derivados de acetileno como agentes anti-inflamatorios/analgesicos |
DE60001623T2 (de) | 1999-12-03 | 2003-12-18 | Pfizer Products Inc., Groton | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
CN1423646A (zh) | 1999-12-03 | 2003-06-11 | 辉瑞产品公司 | 作为抗炎/镇痛剂的杂环-烷基磺酰基吡唑衍生物 |
EP1253921A4 (en) * | 2000-01-28 | 2004-10-13 | Merck & Co Inc | TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS |
ATE298749T1 (de) | 2001-07-05 | 2005-07-15 | Pfizer Prod Inc | Heterocyclo-alkylsulfonyl pyrazole als entzündungshemmende/analgetische mittel |
AR038957A1 (es) | 2001-08-15 | 2005-02-02 | Pharmacia Corp | Terapia de combinacion para el tratamiento del cancer |
GT200200183A (es) | 2001-09-28 | 2003-05-23 | Procedimiento para preparar derivados de heterocicloalquilsulfonil pirazol | |
WO2003037336A1 (en) | 2001-11-02 | 2003-05-08 | Pfizer Products Inc. | 1-(5-sulfonyl-pyridin-2-yl)-5-(methylidene-cycloalkylmethoxy)-1h-pyrazole-4-carbonitrile derivatives and other compounds as cyclooxygenase inhibitors for the treatment of arthritis, neurodegeneration and colon cancer |
UY27939A1 (es) | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | Compuestos |
CN1309717C (zh) * | 2003-06-03 | 2007-04-11 | 李小虎 | 4-芳基-5h-噻吩-2-酮衍生物、其制法和用途 |
US8067464B2 (en) | 2004-10-04 | 2011-11-29 | Nitromed, Inc. | Compositions and methods using apocynin compounds and nitric oxide donors |
DE602005013116D1 (de) | 2004-12-23 | 2009-04-16 | Glaxo Group Ltd | Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten |
WO2007016677A2 (en) | 2005-08-02 | 2007-02-08 | Nitromed, Inc. | Nitric oxide enhancing antimicrobial compounds, compositions and methods of use |
CN101522627A (zh) * | 2005-08-19 | 2009-09-02 | 爱密斯菲尔科技公司 | 用于递送活性剂的环丙基化合物和组合物 |
AU2007243765A1 (en) | 2006-03-29 | 2007-11-08 | Nicox S.A. | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use |
EP1878717A1 (en) | 2006-07-14 | 2008-01-16 | Bayer Schering Pharma Aktiengesellschaft | Benzyl amines, a process for their production and their use as anti-inflammatory agents |
GB0704407D0 (en) | 2007-03-07 | 2007-04-18 | Glaxo Group Ltd | Compounds |
US7943658B2 (en) | 2007-07-23 | 2011-05-17 | Bristol-Myers Squibb Company | Indole indane amide compounds useful as CB2 agonists and method |
EP2062880A1 (en) | 2007-11-22 | 2009-05-27 | Bayer Schering Pharma Aktiengesellschaft | 5-[(3,3,3-Trifluoro-2-hydroxy-1-arylpropyl)amino]-1H-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents |
GB0813144D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
EP2177215A1 (en) | 2008-10-17 | 2010-04-21 | Laboratorios Del. Dr. Esteve, S.A. | Co-crystals of tramadol and NSAIDs |
WO2011012622A1 (en) | 2009-07-30 | 2011-02-03 | Glaxo Group Limited | Benzoxazinone derivatives for the treatment of glytl mediated disorders |
WO2011023753A1 (en) | 2009-08-27 | 2011-03-03 | Glaxo Group Limited | Benzoxazine derivatives as glycine transport inhibitors |
GB201000685D0 (en) | 2010-01-15 | 2010-03-03 | Glaxo Group Ltd | Novel compounds |
GB201007789D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel Compound |
GB201007791D0 (en) | 2010-05-10 | 2010-06-23 | Glaxo Group Ltd | Novel compounds |
ES2529233T3 (es) | 2010-07-09 | 2015-02-18 | Convergence Pharmaceuticals Limited | Compuestos tetrazol como bloqueadores de canales de calcio |
JP6058556B2 (ja) | 2011-01-19 | 2017-01-11 | クオンベルゲンセ プハルマセウトイカルス リミテッド | CaV2.2カルシウムチャンネルブロッカーとしてのピペラジン誘導体 |
GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
WO2014047519A2 (en) | 2012-09-21 | 2014-03-27 | Rhode Island Hospital | Inhibitors of beta-hydrolase for treatment of cancer |
GB201417500D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
GB201417499D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
GB201417497D0 (en) | 2014-10-03 | 2014-11-19 | Convergence Pharmaceuticals | Novel use |
CN104803956A (zh) * | 2015-03-06 | 2015-07-29 | 江苏天和制药有限公司 | 非罗考昔的一种合成方法 |
EP3292213A1 (en) | 2015-05-04 | 2018-03-14 | Academisch Medisch Centrum | Biomarkers for the detection of aspirin insensitivity |
PL3609877T3 (pl) | 2017-04-14 | 2021-06-28 | Cosma S.P.A. | Sposób syntezy firokoksybu |
CN108178724B (zh) * | 2017-12-22 | 2020-09-11 | 四川大学 | 化合物的制备方法 |
CN110240537B (zh) * | 2019-05-22 | 2022-06-21 | 成都阿奇生物医药科技有限公司 | 一种茚氧乙酸类化合物及其制备方法和用途 |
CN110452198B (zh) * | 2019-09-03 | 2021-03-26 | 山东鲁抗舍里乐药业有限公司 | 一种非罗考昔的制备方法 |
CN110452199B (zh) * | 2019-09-03 | 2021-03-30 | 山东鲁抗舍里乐药业有限公司 | 一种非罗考昔的制备方法 |
DE102019214427A1 (de) | 2019-09-23 | 2021-03-25 | Multivac Marking & Inspection Gmbh & Co. Kg | Etikettierer mit Montageeinrichtung für Andrückelement |
CN110746390B (zh) * | 2019-11-14 | 2022-12-30 | 中国科学技术大学 | 制备5-甲酰基-2-呋喃甲酸酯的方法 |
CA3209491A1 (en) | 2021-03-15 | 2022-09-22 | Saul Yedgar | Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory disease |
CN113248458B (zh) * | 2021-05-27 | 2022-09-27 | 陕西省煤田地质集团有限公司 | 一种α-羰基酰胺化合物的制备方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5474995A (en) * | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
AU702591B2 (en) * | 1994-12-21 | 1999-02-25 | Merck Frosst Canada Ltd. | Diaryl-2-(5H)-furanones as cox-2 inhibitors |
-
1996
- 1996-09-10 UA UA98041875A patent/UA57002C2/uk unknown
- 1996-10-07 HR HR960458A patent/HRP960458B1/xx not_active IP Right Cessation
- 1996-10-08 MY MYPI96004167A patent/MY141773A/en unknown
- 1996-10-09 HU HU9802506A patent/HU222785B1/hu active Protection Beyond IP Right Term
- 1996-10-09 ES ES96932417T patent/ES2187675T3/es not_active Expired - Lifetime
- 1996-10-09 AT AT96932417T patent/ATE229515T1/de active
- 1996-10-09 BR BR9611015-5A patent/BR9611015A/pt not_active IP Right Cessation
- 1996-10-09 NZ NZ319090A patent/NZ319090A/xx not_active IP Right Cessation
- 1996-10-09 PE PE1996000715A patent/PE17198A1/es not_active IP Right Cessation
- 1996-10-09 PL PL96326203A patent/PL188918B1/pl unknown
- 1996-10-09 DZ DZ960147A patent/DZ2103A1/fr active
- 1996-10-09 PT PT96932417T patent/PT863891E/pt unknown
- 1996-10-09 JP JP51537197A patent/JP3337476B2/ja not_active Expired - Lifetime
- 1996-10-09 AU AU71236/96A patent/AU703871B2/en not_active Expired
- 1996-10-09 EA EA199800290A patent/EA000795B1/ru not_active IP Right Cessation
- 1996-10-09 DE DE69625374T patent/DE69625374T2/de not_active Expired - Lifetime
- 1996-10-09 SK SK450-98A patent/SK282639B6/sk not_active IP Right Cessation
- 1996-10-09 CN CNB961976098A patent/CN1203066C/zh not_active Expired - Lifetime
- 1996-10-09 IL IL12369996A patent/IL123699A/en not_active IP Right Cessation
- 1996-10-09 CA CA002233178A patent/CA2233178C/en not_active Expired - Lifetime
- 1996-10-09 DK DK96932417T patent/DK0863891T3/da active
- 1996-10-09 KR KR10-1998-0702755A patent/KR100354940B1/ko not_active IP Right Cessation
- 1996-10-09 EE EE9800080A patent/EE03969B1/xx active Protection Beyond IP Right Term
- 1996-10-09 EP EP96932417A patent/EP0863891B1/en not_active Expired - Lifetime
- 1996-10-09 WO PCT/CA1996/000682 patent/WO1997014691A1/en active IP Right Grant
- 1996-10-09 RO RO98-00856A patent/RO119884B1/ro unknown
- 1996-10-09 TR TR1998/00585T patent/TR199800585T2/xx unknown
- 1996-10-09 CZ CZ19981101A patent/CZ295764B6/cs not_active IP Right Cessation
- 1996-10-09 DE DE200512000010 patent/DE122005000010I2/de active Active
- 1996-10-10 CO CO96053995A patent/CO4770965A1/es unknown
- 1996-10-10 RS YUP-548/96A patent/RS49885B/sr unknown
- 1996-10-12 TW TW085112463A patent/TW426679B/zh not_active IP Right Cessation
- 1996-10-30 SA SA96170405A patent/SA96170405B1/ar unknown
-
1998
- 1998-03-20 IS IS4695A patent/IS2148B/is unknown
- 1998-04-08 MX MX9802836A patent/MX9802836A/es unknown
- 1998-04-08 NO NO19981628A patent/NO321042B1/no not_active IP Right Cessation
- 1998-05-04 BG BG102425A patent/BG63391B1/bg unknown
-
1999
- 1999-05-07 HK HK99102061A patent/HK1016980A1/xx not_active IP Right Cessation
-
2000
- 2000-12-01 JP JP2000366579A patent/JP4068802B2/ja not_active Expired - Lifetime
-
2005
- 2005-02-14 NL NL300175C patent/NL300175I2/nl unknown
- 2005-03-09 LU LU91145C patent/LU91145I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9611015A (pt) | Composto, composição farmacêutica e processo para o tratamento de uma doença inflamatória suscetìvel ao tratamento com um agente não-tóxico anti-inflamatório não-esteróide, sal farmaceuticamente aceitável, utilização de um composto | |
BR9406979A (pt) | Composto,composicão farmaceutica para tratar uma doenca inflamatória suscetivel de tratamento com um agente anti- inflamatório nao esteroidal processos para tratar uma doenca inflamatória e para preparar um composto sal famacéuticamente aceitável uso de um composto composicão farmaceutica anti-inflamatória nao esteroidal | |
BRPI9710372B8 (pt) | composto, e, composição farmacêutica. | |
ATE208397T1 (de) | Arylsubstituierte 5,5 verknüpfte aromatische nitroverbindungen als entzündungshemmende wirkstoffe | |
BR9711194A (pt) | Uso de agente quelante clioquinol para a fabricação de uma composição farmacêutica para o tratamento de doença de alzheimer. | |
RU94041223A (ru) | Средство для лечения мотонейроновых заболеваний | |
BR9509683A (pt) | Compostos e processos para tratar uma condição clínica em um mamífero para tratar uma condição hiperlipidêmica em um manífero e para a preparação de um composto | |
BR0108600A (pt) | Composto, processo para a preparação do mesmo, composição farmacêutica, processo para a preparação da mesma, uso de um composto, e, métodos para tratamento de uma doença mediada por quimiocina e para tratamento de uma doença inflamatória | |
PA8452201A1 (es) | Derivados de 9-desoxo-9a-aza-9a -homoeritromicina a c-4"sustituidos. | |
BR9408478A (pt) | Composto composição farmacéutica processos de tratmento de uma doença suscetível ao tratamento com agente anti-inflamatório não esteroidal e de tratamento de doenças medidas pela ciclo-oxigenase, sal farmaceuticamente eficaz e uso de um composto | |
PT828724E (pt) | Diaril-5-oxigenadas-2-(5h)-furanonas comoinibidoras de cox-2 | |
LV12632A (lv) | Pyrazoline derivatives their preparation and application as medicaments | |
PA8452001A1 (es) | Derivados de macrolidos c-4" sustituidos | |
AR020727A1 (es) | Uso de compuestos derivados 3-amino-4-aril-maleimidas para la preparacion de medicamentos para condiciones asociadas a una necesidad de inhibicion de lagsk-3, dichos compuestos, procedimiento para su preparacion y composiciones farmaceuticas que los comprenden | |
ATE189218T1 (de) | Bicyclische diarylheterocyclen als cyclooxygenase-2-inhibitoren | |
KR950700258A (ko) | 레티노이드 수용체(rar)에 결합하는 헤테로고리 탄산유도체(heterocyclic carbonic acid derivatives which bind to retinoid receptors(rar)) | |
KR900017590A (ko) | 좌창(Acne)치료방법 및 그 약제 조성물 | |
AR019853A1 (es) | Derivado del acido 3-aril-2-hidroxipropionico, proceso e intermediario para su preparacion, formulaciones farmaceuticas, uso de dicho compuesto en laelaboracion de un medicamento, metodo para la profilaxis y/o tratamiento de trastornos clinicos asociados con la resistencia a la insulina, y formulaci | |
MX9501848A (es) | Nuevos compuestos polienicos, composiciones farmaceuticas y cosmeticas que los contienen y sus usos. | |
BRPI0111140B8 (pt) | forma polimórfica, uso da mesma, e, composição farmacêutica | |
EA199700380A1 (ru) | Бициклические ароматические соединения, фармацевтическая и косметическая композиции на их основе и применение косметической композиции | |
GT199900015A (es) | Procedimiento para tratar la insuficiencia cardiaca | |
BR9713921A (pt) | Composto, composição farmacêutica, processo para tógico capaz de ser modulado através da inibição do fator xa | |
BRPI0005616B8 (pt) | 2-(3,5-bis-trifluormetil-fenil)-n-metil-n-(6-morfolin-4-il-4-o-tolil-piridin-3-il)-isobutiramida, seu processo de preparação e seu uso, bem como medicamento | |
CO5011084A1 (es) | Composiciones y metodos para tratar trastornos respiratorios |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Transfer |
Free format text: MERCK FROSST CANADA & CO./MERCK FROSST CANADA & CIE. (CA) |
|
FB36 | Technical and formal requirements: requirement - article 36 of industrial property law | ||
HJEG | Technical examination (opinion): technical examination (opinion) related to article 229 of industrial property law | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: MERCK FROSST CANADA LTD. (CA) Free format text: TRANSFERIDO DE: MERCK FROSST CANADA AND CO./MERCK FROSST CANADA AND CIE. |
|
B25D | Requested change of name of applicant approved |
Owner name: MERCK CANADA INC. (CA) |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 09/10/2016 |